Figure S4. Kaplan-Meier PFS estimates in the (A) ITT, (B) TC3 or IC3, (C) TC2/3 or IC2/3, (D) TC1/2/3 or IC1/2/3, and (E) TC0 and IC0 subgroups in the OAK ITT1225 secondary population. HRs were stratified for ITT, TC3 or IC3, TC2/3 or IC2/3, and TC1/2/3 or IC1/2/3 subgroups and unstratified for the TC0 and IC0 subgroup. TC3 or IC3, PD-L1 expression on 50% of TC or 10% of IC; TC2/3 or IC2/3, PD-L1 ≥ ≥ expression on 5% of TC or IC; TC1/2/3 or IC1/2/3, PD-L1 expression on 1% of TC ≥ ≥ or IC; TC0 and IC0, PD-L1 expression on < 1% of TC and IC. Data cutoff: January 23, 2017. HR, hazard ratio; ITT, intention-to-treat; PFS, progression-free survival. A
Figure S4. Kaplan-Meier PFS estimates in the (A) ITT, (B) TC3 or IC3, (C) TC2/3 or IC2/3, (D) TC1/2/3 or IC1/2/3, and (E) TC0 and IC0 subgroups in the OAK ITT1225 secondary population. HRs were stratified for ITT, TC3 or IC3, TC2/3 or IC2/3, and TC1/2/3 or IC1/2/3 subgroups and unstratified for the TC0 and IC0 subgroup. TC3 or IC3, PD-L1 expression on ≥ 50% of TC or ≥ 10% of IC; TC2/3 or IC2/3, PD-L1 expression on ≥ 5% of TC or IC; TC1/2/3 or IC1/2/3, PD-L1 expression on ≥ 1% of TC or IC; TC0 and IC0, PD-L1 expression on < 1% of TC and IC. Data cutoff: January 23, 2017. HR, hazard ratio; ITT, intention-to-treat; PFS, progression-free survival. A
1-s2.0-S1556086418306117-mmc1.docx